Does Insurance Cover Wegovy or Zepbound? (2026)

The first question most people ask about Wegovy and Zepbound is not "how do they work" — it's "will my insurance pay for this?" That's understandable. Brand-name GLP-1 medications can cost more than $1,000 per month without coverage, and the answer varies significantly depending on your plan, your employer, and your state.

The short version: some commercial plans cover these drugs, most don't, and Medicare currently doesn't cover them for weight loss at all. But the picture is more nuanced than a flat yes or no — and knowing exactly where your plan stands can save you hundreds of dollars a month.

The Short Answer

Wegovy (semaglutide) received FDA approval for chronic weight management in adults in June 2021. Zepbound (tirzepatide) followed in November 2023. Both are the same active ingredients used in diabetes medications (Ozempic and Mounjaro, respectively), but they carry distinct FDA approvals for weight loss at higher doses.

Insurance coverage depends entirely on your plan. Employer-sponsored plans set their own formularies. Medicare Part D is legally barred from covering weight-loss-only drugs under current federal law. Medicaid coverage varies state by state.

If your plan does cover these drugs, you'll almost certainly need prior authorization first. If your plan doesn't, you still have options — including manufacturer savings programs and telehealth providers that specialize in self-pay access.

How GLP-1 Coverage Works

Insurance companies decide which drugs to cover through a document called a formulary. GLP-1 agonists approved for weight loss are a relatively new category, and many plans have not added them — or have added them with significant restrictions.

Even when Wegovy or Zepbound appears on a plan's formulary, it typically lands on a high-cost specialty tier. That means you pay a percentage of the drug's cost rather than a flat copay, and the prior authorization process — where a clinician documents medical necessity — becomes a gatekeeper. Coverage denials are common, and even approved claims can be reversed on refill if insurers decide ongoing use doesn't meet their criteria.

The upstream question is simpler: does your plan cover GLP-1 drugs for weight loss at all? That's what this article addresses. Once you know coverage exists, the detailed steps to actually secure it are covered in our prior authorization guide.

Commercial Insurance (Employer Plans)

Employer-sponsored insurance is the most common source of coverage — and also the most variable. Employers choose their own benefits packages, which means two people working at different companies in the same city could have completely different coverage for the exact same drug.

Coverage is still a minority position. According to the KFF 2024 Employer Health Benefits Survey, 18% of firms with 200 or more employees cover GLP-1 agonists when used primarily for weight loss. Among the largest employers (1,000+ employees), that figure rises to 25%. But among firms not currently covering these drugs, 62% said they are unlikely to start within the next year.

A few things tend to predict whether your employer plan covers GLP-1s for weight loss:

• Employer size. Large self-insured employers are more likely to cover it, because they bear the cost directly and can weigh the long-term health benefits of managed obesity treatment.
• Plan type. PPO plans tend to have broader formularies than HMO plans. High-deductible health plans vary widely.
• Industry. Healthcare, tech, and finance employers have been earlier adopters. Coverage is less common in retail, food service, and other sectors with thinner margins.

The clearest path to finding out is checking your plan's formulary directly — more on that below.

Medicare and Medicaid

Medicare Part D currently does not cover Wegovy or Zepbound when prescribed solely for weight loss. This is not a formulary decision by individual plans — it reflects a longstanding statutory exclusion. Under federal law, Medicare Part D plans are prohibited from covering drugs used for "anorexia, weight loss, or weight gain," a restriction that predates the GLP-1 era and has not yet been updated.

That may change. Legislation has been proposed in Congress — including the TREAT Act — that would direct Medicare to cover anti-obesity medications. As of April 2026, no final rule expanding Medicare coverage to weight-loss GLP-1s has been enacted. If Wegovy or Zepbound is prescribed for a covered condition like type 2 diabetes (using Ozempic or Mounjaro, which are the diabetes-indication equivalents), Medicare can cover those versions under existing formulary rules.

Medicaid coverage is a state-by-state question. Some states have added Wegovy or Zepbound to their Medicaid formularies with specific clinical criteria; others have not. Medicaid enrollees should check with their state agency or managed care plan directly, since coverage decisions change and vary significantly.

Which Insurers Are Most Likely to Cover It

No comprehensive public list exists of every insurer that covers GLP-1s for weight loss, because coverage decisions happen at the plan level — not the insurer level. A single insurer like UnitedHealthcare may offer dozens of plans, some with GLP-1 coverage and some without.

That said, some general patterns hold:

• Blue Cross Blue Shield plans in several states have added Wegovy and Zepbound to their formularies with prior authorization requirements. Coverage depends on the specific BCBS plan and state affiliate.
• Cigna and Aetna have covered GLP-1s in some employer plan tiers, again with prior authorization.
• UnitedHealthcare has included GLP-1s on some commercial plan formularies, often with step therapy requirements (meaning you must try and fail a different medication first).

These patterns can shift. Insurers periodically add or remove drugs based on cost negotiations, outcomes data, and their own pharmacy benefit manager decisions. The only reliable answer is to check your own plan's current formulary.

What Typically Triggers a Denial

Even when a plan covers GLP-1s, claims get denied regularly. The most common reasons:

No qualifying BMI. Most plans set a BMI threshold — typically 30 or above, or 27 with at least one weight-related comorbidity (such as high blood pressure, type 2 diabetes, or sleep apnea). A claim submitted without documentation of the qualifying BMI or comorbidity will be denied.

No prior authorization on file. Wegovy and Zepbound almost always require prior authorization before a prescription can be filled. Trying to fill without it typically results in an automatic rejection at the pharmacy.

Step therapy not completed. Some plans require you to first try and document failure with a cheaper intervention (sometimes another weight-loss drug, sometimes a supervised diet program) before approving a GLP-1.

Prescription written for the wrong indication. If the prescription doesn't clearly specify weight management and cites appropriate diagnostic codes, claims can be denied on technical grounds.

Formulary exclusion. The plan simply doesn't cover weight-loss GLP-1s. This isn't something that can be overridden by the provider — you'd need to appeal to add the drug to your plan's formulary, which is a longer process typically reserved for the next benefits renewal cycle.

How to Check Your Own Plan

Step 1: Find your plan's formulary. Log into your insurer's member portal and look for "drug list," "formulary," or "prescription coverage." Search for "semaglutide" and "tirzepatide" — not the brand names, since drugs are indexed by generic name.

Step 2: Note the tier and requirements. If the drug appears, check what tier it's on and whether prior authorization, step therapy, or quantity limits are listed.

Step 3: Call member services. The formulary document tells you what's possible, but a member services call confirms the current status. Ask specifically: "Is Wegovy/Zepbound covered for weight management on my current plan? What are the prior authorization requirements?"

Step 4: Ask your prescribing provider. Telehealth providers that offer insurance coordination — like Ro, PlushCare, and Mochi Health — have internal teams experienced with specific insurer requirements and can often identify coverage gaps or opportunities before you go through the prior auth process.

Providers That Help With Insurance

Not all GLP-1 telehealth platforms handle insurance the same way. Some are strictly self-pay. Others have built insurance coordination into their model.

Ro includes insurance coordination as part of its membership. The Ro clinical team can submit prior authorization paperwork and follow up with your insurer. This is particularly useful if your plan likely covers GLP-1s but requires documentation — Ro's team knows the process and the common insurer-specific requirements.

PlushCare is built around insurance-first care. PlushCare physicians are in-network with most major insurers, which means visits may be covered under your medical benefit rather than your pharmacy benefit. Their providers are experienced at writing prior authorization documentation that meets insurer criteria.

Found offers a free insurance check at sign-up, which can quickly tell you whether your plan covers GLP-1s before you commit to anything. Found works with more than 10 medications, which gives them flexibility to prescribe alternatives if your specific plan doesn't cover Wegovy or Zepbound.

Mochi Health also has an insurance integration team and works with commercial insurers on prior authorization for brand-name medications.

Hims, by contrast, does not actively assist with insurance prior authorization. Hims is built around direct self-pay access — primarily brand-name Wegovy — and is better suited to people who've already confirmed their plan won't cover GLP-1s or who prefer to pay out of pocket.

What to Do If You're Not Covered

If your plan doesn't cover Wegovy or Zepbound for weight loss, you have several practical paths forward.

Manufacturer savings programs. Novo Nordisk (maker of Wegovy) and Eli Lilly (maker of Zepbound) offer savings cards and patient assistance programs for eligible patients. Eligibility requirements and discount amounts change periodically, so check directly with each manufacturer's website for current terms.

Self-pay compounded semaglutide or tirzepatide. Compounded GLP-1 medications — which are not FDA-approved as finished products and use the same active ingredient as the brand-name versions — can cost significantly less per month through self-pay telehealth providers. Providers like Henry Meds and TrimRx specialize in affordable self-pay access. The tradeoff is that compounded formulations have not been studied in the large-scale clinical trials conducted for brand-name Wegovy and Zepbound — the long-term evidence base is less established.

Appeal a denial. If your plan denied prior authorization, you have the right to appeal. A formal appeal, especially one that includes a letter of medical necessity from your provider and supporting clinical documentation, succeeds more often than people expect. Some telehealth providers assist with this process.

Wait for your benefits cycle. If your employer plan doesn't cover GLP-1s now, coverage decisions are typically revisited at the next annual benefits renewal. If you work at a larger employer, it may be worth raising the issue with HR — especially if the KFF data showing 25% of large employers now cover these drugs gives you a benchmark to reference.

For a fuller breakdown of what to do once you don't have coverage, including specific self-pay cost comparisons, see our GLP-1 without insurance guide.

---